Santen Pharmaceutical , Ltd. Return on Equity

Santen Pharmaceutical , Ltd. (SNPHY) currently reports a ROE of 13.03%. That is above the sector sector average of -6.13%. Use the charts on this page to explore Santen Pharmaceutical , Ltd.'s ROE history and peer comparisons.

Santen Pharmaceutical , Ltd.'s ROE of 13.03% is higher than the its sector sector average of -6.13%. That is roughly 312.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Santen Pharmaceutical , Ltd.'s current 13.03% should be judged against industry norms (sector average: -6.13%) and against SNPHY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 13.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -6.13%. From there, open related valuation or income-statement pages for Santen Pharmaceutical , Ltd., and consider following SNPHY for alerts when major investors trade the stock.